The Nashville-based managed services organization now serves 1300 providers and 747,000 patients across 420 sites of care.

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Using vedolizumab first, before tumor necrosis facor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

Hospitalized patients with opioid use disorder (OUD) who received in-hospital addiction consultation services were more ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Taxing imports to the US could spell major consequences for health care prices, innovation, and access, as a great amount of ...

Patient navigation and mailed outreach improved colorectal cancer screening rates in rural clinics, but follow-up colonoscopy ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy ...